Michele Aieta

4.3k total citations
116 papers, 2.3k citations indexed

About

Michele Aieta is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Michele Aieta has authored 116 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 69 papers in Pulmonary and Respiratory Medicine and 28 papers in Cancer Research. Recurrent topics in Michele Aieta's work include Lung Cancer Treatments and Mutations (25 papers), Lung Cancer Research Studies (17 papers) and Renal cell carcinoma treatment (16 papers). Michele Aieta is often cited by papers focused on Lung Cancer Treatments and Mutations (25 papers), Lung Cancer Research Studies (17 papers) and Renal cell carcinoma treatment (16 papers). Michele Aieta collaborates with scholars based in Italy, United States and Australia. Michele Aieta's co-authors include Alfredo Tartarone, Vincenza Conteduca, Rosa Lerose, Giuseppe Di Lorenzo, Ugo De Giorgi, Sabino De Placido, Giandomenico Roviello, Dino Amadori, Emanuela Scarpi and Teodoro Sava and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Michele Aieta

113 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michele Aieta Italy	24	1.2k	997	638	600	315	116	2.3k
Som D. Mukherjee Canada	25	968 0.8×	499 0.5×	560 0.9×	414 0.7×	415 1.3×	85	2.0k
Sandra J. Strauss United Kingdom	30	1.3k 1.1×	1.5k 1.5×	844 1.3×	418 0.7×	261 0.8×	94	3.1k
Jean‐Emmanuel Kurtz France	28	891 0.7×	1.1k 1.1×	420 0.7×	248 0.4×	364 1.2×	113	2.6k
Giacomo Cartenì Italy	27	1.7k 1.4×	1.4k 1.4×	648 1.0×	521 0.9×	864 2.7×	110	3.2k
Guillermo López-Vivanco Spain	21	1.3k 1.1×	1.0k 1.0×	677 1.1×	405 0.7×	206 0.7×	116	2.1k
Anne Floquet France	30	1.3k 1.1×	758 0.8×	442 0.7×	521 0.9×	665 2.1×	170	3.3k
Fariba Navid United States	31	896 0.7×	1.3k 1.3×	686 1.1×	298 0.5×	416 1.3×	104	2.8k
M. Nooij Netherlands	29	1.4k 1.2×	1.3k 1.3×	446 0.7×	778 1.3×	297 0.9×	45	2.9k
Paolo Bidoli Italy	27	2.0k 1.6×	1.9k 1.9×	531 0.8×	292 0.5×	365 1.2×	127	3.1k
Andrea J. Bullock United States	21	1.2k 1.0×	491 0.5×	505 0.8×	449 0.7×	295 0.9×	92	2.2k

Countries citing papers authored by Michele Aieta

Since Specialization

Citations

This map shows the geographic impact of Michele Aieta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele Aieta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele Aieta more than expected).

Fields of papers citing papers by Michele Aieta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michele Aieta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele Aieta. The network helps show where Michele Aieta may publish in the future.

Co-authorship network of co-authors of Michele Aieta

This figure shows the co-authorship network connecting the top 25 collaborators of Michele Aieta. A scholar is included among the top collaborators of Michele Aieta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele Aieta. Michele Aieta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Damato, Angela, Domenico Bilancia, Francesco Iachetta, et al.. (2024). Phase II randomized study of maintenance therapy with regorafenib (REGO) versus placebo after first-line platinum and fluoropyrimidines-based chemotherapy in HER2 negative locally advanced/metastatic gastric (GC) or gastroesophageal junction (GEJ) cancer: Results of a-MANTRA study (GOIRC-05-2016).. Journal of Clinical Oncology. 42(16_suppl). 4056–4056. 1 indexed citations

Laurino, Simona, Mariarita Brancaccio, Tiziana Angrisano, et al.. (2023). Role of IL-6/STAT3 Axis in Resistance to Cisplatin in Gastric Cancers. Biomedicines. 11(3). 694–694. 16 indexed citations

Conté, Pierfranco, Antonio Frassoldati, Giancarlo Bisagni, et al.. (2021). 41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial. Annals of Oncology. 32. S37–S37. 4 indexed citations

Rossi, Elisabetta, Michele Aieta, Alfredo Tartarone, et al.. (2021). A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients. Translational Lung Cancer Research. 10(1). 80–92. 23 indexed citations

Russi, Sabino, Viviana Maresca, Pietro Zoppoli, et al.. (2020). Effect of Feijoa Sellowiana Acetonic Extract on Proliferation Inhibition and Apoptosis Induction in Human Gastric Cancer Cells. Applied Sciences. 10(21). 7756–7756. 7 indexed citations

Roviello, Giandomenico, Silvia Paola Corona, Michele Aieta, & Raheleh Roudi. (2019). Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy. Cancer Biotherapy and Radiopharmaceuticals. 34(3). 141–146. 2 indexed citations

Roviello, Giandomenico, et al.. (2019). Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel. Anti-Cancer Drugs. 30(7). 745–748. 2 indexed citations

Roviello, Giandomenico, et al.. (2019). The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. Investigational New Drugs. 37(3). 524–530. 2 indexed citations

Roviello, Giandomenico, et al.. (2018). Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer. Medicine. 97(20). e10745–e10745. 9 indexed citations

10.

Conté, Pierfranco, Valentina Guarneri, Giancarlo Bisagni, et al.. (2018). 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio. Annals of Oncology. 29. viii705–viii705. 5 indexed citations

11.

Tartarone, Alfredo, Rosa Lerose, & Michele Aieta. (2018). Is there a role for immunotherapy in malignant pleural mesothelioma?. Medical Oncology. 35(7). 98–98. 3 indexed citations

12.

Conteduca, Vincenza, Orazio Caffo, Cristian Lolli, et al.. (2017). Long‐term clinical impact of PSA surge in castration‐resistant prostate cancer patients treated with abiraterone. The Prostate. 77(9). 1012–1019. 7 indexed citations

13.

Manicone, Mariangela, Maria Chiara Scaini, Maria Grazia Rodriquenz, et al.. (2017). Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared. Journal of Thoracic Disease. 9(S13). S1391–S1396. 7 indexed citations

14.

Giorgi, Ugo De, Karim Rihawi, Michele Aieta, et al.. (2014). Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. Journal of Geriatric Oncology. 5(2). 156–163. 22 indexed citations

15.

Gnoni, Antonio, Antonella Licchetta, Aldo Scarpa, et al.. (2013). Carcinogenesis of Pancreatic Adenocarcinoma: Precursor Lesions. International Journal of Molecular Sciences. 14(10). 19731–19762. 50 indexed citations

16.

Bianchino, Gabriella, Achille Cittadini, Vitina Grieco, et al.. (2011). Polymorphisms of the CYP1A1, CYP2E1 and XRCC1 genes and cancer risk in a Southern Italian population: a case-control study.. PubMed. 31(4). 1359–65. 10 indexed citations

17.

Tartarone, Alfredo, Rosa Lerose, Giuseppina Gallucci, Raffaele Ardito, & Michele Aieta. (2011). Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer. Medical Oncology. 29(3). 1599–1605. 3 indexed citations

18.

Gallucci, Giuseppina, Giovanni Storto, Alfredo Tartarone, et al.. (2010). The Clinical Impact of a Cardiologic Follow-up in Breast Cancer Survivors: An Observational Study. International Journal of Immunopathology and Pharmacology. 23(4). 1221–1227. 6 indexed citations

19.

Zupa, Angela, Alessandro Sgambato, Gabriella Bianchino, et al.. (2009). GSTM1 and NAT2 polymorphisms and colon, lung and bladder cancer risk: a case-control study.. PubMed. 29(5). 1709–14. 30 indexed citations

20.

Lorenzo, Giuseppe Di, Riccardo Autorino, Giacomo Cartenì, et al.. (2009). Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Annals of Oncology. 20(9). 1535–1542. 169 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact